Table 2 Summary of follow-up results
Total number of patients | 60 | ||
|---|---|---|---|
Disease recurrence | No | 44(73.3%) | |
Yes | 16(26.7%) | ||
Histology of recurrence | T1-High grade | 4(25.0%) | |
Ta-High grade | 2(12.5%) | ||
Ta-Low grade | 10(62.5%) | ||
Salvage therapy | Cystectomy | 4(25.0%) | |
Mitomycine C | 6(37.5%) | ||
Surveillance cystoscopy & TURBT | 6(37.5%) | ||
Further recurrence | No | 52(86.7%) | |
Yes | 8(13.3%) | ||
Histology further recurrence | T1-Low grade | 1(12.5%) | |
Ta-Low grade | 7(87.5%) | ||
Further Salvage therapy | Cystectomy | 1(12.5%) | |
Mitomycine C | 2(25%) | ||
Surveillance cystoscopy & TURBT | 5(62.5%) | ||
Disease progression | No | 55(91.7%) | |
Yes | 5( 8.3%) | ||
Histology of progression | T1-High grade | 3(60.0%) | |
T2 | 2(40.0%) | ||
Further Salvage therapy | Cystectomy | 2(40.0%) | |
Surveillance cystoscopy & TURBT | 2(40.0%) | ||
Systemic chemotherapy | 1(20.0%) | ||
Outcome | Alive | 58(96.7%) | |
Death from other cause ( one, myocardial infarction and one, sepsis secondary to perforated neobladder) | 2(3.3%) | ||